{"filing":{"accession_number":"0001213900-26-111493","cik":"0001871321","ticker":"DRTSW","company_name":"Alpha Tau Medical Ltd.","form":"6-K","filing_date":"2026-10-22","report_date":"2026-10-22","primary_document":"ea0309330-6k_alpha.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1871321/000121390026111493/ea0309330-6k_alpha.htm"},"events":[{"id":37076,"run_id":34176,"accession_number":"0001213900-26-111493","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"Alpha Tau announced the signing of a Memorandum of Understanding (MOU) with Samsung Medical Center to explore a potential clinical trial of Alpha DaRT for pancreatic cancer patients in South Korea. This represents a material operational and strategic milestone—the company's first clinical trial in Korea and expansion of its pancreatic cancer program to a sixth country. While not a discrete M\u0026A transaction, the MOU signals meaningful progress in the company's clinical development and geographic expansion strategy, which would affect a reasonable investor's assessment of the registrant's pipeline and market opportunities.","company_name":"Alpha Tau Medical Ltd.","ticker":"DRTSW","filing_date":"2026-10-22","form":"6-K","submitted_at":null,"items":[{"id":41670,"accession_number":"0001213900-26-111493","item_number":"EX-99.1","item_title":"ea030933001ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Alpha Tau announced the signing of a Memorandum of Understanding (MOU) with Samsung Medical Center to explore a potential clinical trial of Alpha DaRT for pancreatic cancer patients in South Korea. This represents a material operational and strategic milestone—the company's first clinical trial in Korea and expansion of its pancreatic cancer program to a sixth country. While not a discrete M\u0026A transaction, the MOU signals meaningful progress in the company's clinical development and geographic expansion strategy, which would affect a reasonable investor's assessment of the registrant's pipeline and market opportunities.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-10-22T12:31:56.512028+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":41670,"accession_number":"0001213900-26-111493","item_number":"EX-99.1","item_title":"ea030933001ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Alpha Tau announced the signing of a Memorandum of Understanding (MOU) with Samsung Medical Center to explore a potential clinical trial of Alpha DaRT for pancreatic cancer patients in South Korea. This represents a material operational and strategic milestone—the company's first clinical trial in Korea and expansion of its pancreatic cancer program to a sixth country. While not a discrete M\u0026A transaction, the MOU signals meaningful progress in the company's clinical development and geographic expansion strategy, which would affect a reasonable investor's assessment of the registrant's pipeline and market opportunities.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-10-22T12:31:56.512028+00:00","company_name":"Alpha Tau Medical Ltd.","ticker":"DRTSW","filing_date":"2026-10-22"}]}